Welcome, this website is intended for international healthcare professionals with an interest in the treatment of Advanced Prostate Cancer. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

Practice shaping data: CHAARTED and FIRSTANA trials

Esmo 2 Practice shaping data- CHAARTED and FIRSTANA trials

Prof. Eleni Efstathiou  and  Dr. Nina Tunariu in this session discussed about the importance of multi-disciplinary approach in the management of prostate cancer. They discussed specifically about the role of imaging in the appropriate diagnosis and determination of response to therapy. With the help of the results of CHAARTED trial  and FIRSTANA trial they tried to point out the need for appropriate imaging  at regular intervals so as to help tailor therapy especially in patients with high-volume disease or advanced prostate cancer.

Next video

Additional materials

  • Additional resources

    Abstract 720PD: Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial

    Sweeney et al.

    Annals of Oncology 27 (Supplement 6): vi243–vi265, 2016

    Link to full article text: http://annonc.oxfordjournals.org/content/27/suppl_6/720PD.full.pdf​


    Abstract 721PD: FIRSTANA: Health-related quality of life (HRQL) and post-hoc analyses for the phase III study assessing cabazitaxel (C) vs docetaxel (D) in chemotherapy-naïve patients ( pts) with metastatic castration-resistant prostate cancer (mCRPC) 

    Oudard et al.

    Annals of Oncology 27 (Supplement 6): vi243–vi265, 2016

    Link to full article text: http://annonc.oxfordjournals.org/content/27/suppl_6/721PD.full.pdf


    Early data published in NEJM: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

    Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al.

    N Engl J Med 2015 Aug 20;373:737-46.

    Link to full article text: http://www.nejm.org/doi/full/10.1056/NEJMoa1503747


    Early French/Belgium study: hormone-sensitive disease – add docetaxel to ADT, no benefit. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

    Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al.

    Lancet Oncol 2013;14:149-58.

    Link to full article text: http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70560-0/abstract


    Stampede trial: benefit from adding docetaxel. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

    James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR et al.

    Lancet 2016;387:1163-77.

    Link to full article text: https://www.ncbi.nlm.nih.gov/pubmed/26719232


    Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

    Vale CL, Burdett S, Rydzewska LH, Albiges L, Clarke NW, Fisher D, et al.

    Lancet Oncol 2016 Feb;17(2):243-56.

    Link to full article text: https://www.ncbi.nlm.nih.gov/pubmed/26718929

  • Additional materials relating to safety/toxicity:

    ESMO 2016 presented posters will be included here (permissions pending):

     720PD: Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial


    721PD: FIRSTANA: Health-related quality of life (HRQL) and post-hoc analyses for the phase III study assessing cabazitaxel (C) vs docetaxel (D) in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)


    722PD: PROSELICA: Health-related quality of life (HRQL) and post-hoc analyses for the phase 3 study assessing cabazitaxel 20 (C20) vs 25 (C25) mg/m2 post-docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)


    738P: Meta-analysis of randomized clinical trials in metastatic castration resistant prostate cancer: Comparison of hypertension, neurological and psychiatric adverse events on enzalutamide and abiraterone acetate plus prednisone treatment


    740P: Safety of Long-Term Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Patients With Abiraterone Acetate Plus Prednisone for ≥ 4 Years


    749P: Efficacy and safety of enzalutamide (ENZ) vs placebo (PL) in chemotherapy-naïve patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following androgen deprivation therapy (ADT): An Asian multinational study


    760P: A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study


    761P: How should we treat castration-resistant prostate cancer patients who have received androgen deprivation therapy (ADT) plus docetaxel upfront for hormone-sensitive disease? Mature analysis of the GETUG-AFU 15 phase III trial


    764TiP: Cog-Pro: Impact of new generation hormono-therapy on cognitive functions in elderly patients treated for a metastatic prostate cancer


    766TiP: CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent


    767TiP: Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trial


    770TiP: EMBARK: A phase 3, randomized, efficacy and safety study of enzalutamide plus leuprolide, enzalutamide monotherapy and placebo plus leuprolide in men with high-risk nonmetastatic prostate cancer progressing after definitive therapy Download poster